Member Directory - Viral Hepatitis Working Group

Primary tabs

Chair: David Thomas

Objectives:

Promote development of long-acting approaches to the treatment and/or prevention of hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. With HCV infection, the ultimate goal is a ‘test and cure’ approach to elimination. With HBV infection, long-acting formulations to simplify treatment and prevention.
Bring clinical, public health, and regulatory expertise to solve this pharmacological challenge by identifying the optimal drug targets and encouraging their development in partnership with Pharma.
Prioritize existing compounds with the pharmacologic and chemical properties that support long-acting formulation.

Interested in joining?

Please submit your request and your CV to Julia Burnett. Acceptance requires a written nomination from a Hepatitis Working Group member and majority approval.

David Thomas, MD, MPH dthomas@jhmi.edu David Thomas is Director of Infectious Diseases and the Stanhope Bayne-Jones Professor of Medicine at the Johns Hopkins School of Medicine. Conflict of Interest: Has no real or apparent conflicts of interest to report.	Robert Bollinger, MD, MPH rcb@jhmi.edu Dr. Bollinger is Founding Director of the Center for Clinical Global Health Education (CCGHE) and Professor of Infectious Diseases at the Johns Hopkins University (JHU) School of Medicine. Conflict of Interest: Receives royalties from emocha Health, miDiagnostics, consulting fees from Merck, Hologic, and grant funding from emocha Health.
Margaret Burroughs, MD margaret.burroughs@Abbvie.com Peggy is a Group Medical Director and Global Development lead for HCV products at AbbVie Inc. Conflict of Interest: Receives salary support from AbbVie.	Arnab Chatterjee, PhD achatterjee@scripps.edu Arnab is a founding PI at Calibr at Scripps Research and currently leads the chemistry group serving as Vice President of Medicinal Chemistry. Conflict of Interest: Has no real or apparent conflicts of interest to report.
Chari Cohen, MPH, DrPH chari.cohen@hepb.org Dr. Cohen is President of the Hepatitis B Foundation, leading national and international efforts to eliminate hepatitis B through developing partnerships, capacity and strategies to improve hepatitis B and D screening, vaccination, and linkage to care. Conflict of Interest: Receives consulting fees (all paid directly to the Hepatitis B Foundation. She represents the Hepatitis B Foundation on community advisory boards for Gilead Sciences, Roche, Arbutus, and GSK. Also, Hepatitis B Foundation receives research and program grants from Gilead Sciences, Genentech, GSK, VBI Vaccines, and Dynavax Technologies.	Jordan Feld, MD, MPH Jordan.Feld@uhn.ca Dr. Feld attended medical school at the University of Toronto and then completed residency programs in Internal Medicine and Gastroenterology. Conflicts of Interest: Dr. Jordan Feld received Personal fees for scientific consulting from: Abbott, Abbvie, Gilead, Enanta, Roche. Dr. Feld reports receiving grants for research from Abbvie, Gilead, Janssen, Wako/Fujifilm
Simon Fletcher, PhD Simon.Fletcher@gilead.com Simon Fletcher is a Vice President at Gilead Sciences, where he leads a group focused on developing novel therapies for acute and chronic viral infections. Conflict of interest: Dr Fletcher receives a salary from Gilead Sciences, and also holds intellectual property rights/patent, and has an ownership interest with them.	Lobna Gaayeb, PhD lgaayeb@medicinespatentpool.org Lobna Gaayeb manages the Long-Acting Technologies project at the Medicines Patent Pool. She has experience in coordinating international networks and scientific projects. Conflict of Interest: Has no real or apparent conflicts of interest to report.
Leah Johnson, PhD leahjohnson@rti.org Leah Johnson, PhD, is a Senior Research Chemist in the Center for Engineered Systems at RTI International. Conflict of Interest: No real or apparent conflicts of interest to report.	Andrew Owen, PhD, FSB aowen@liverpool.ac.uk Andrew Owen is a Professor in the Department of Molecular and Clinical Pharmacology and Director of the Centre of Excellence in Long-acting Therapeutics (CELT; www.liverpool.ac.uk/CELT) at the University of Liverpool. Conflict of Interest: Dr. Owen has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Tandem Nano Ltd., Gilead, Assembly Biosciences.
Mark Sulkowski, MD msulkowski@jhmi.edu Mark Sulkowski, MD, is a Professor of Medicine at the Johns Hopkins University School of Medicine and the Director of the Division of Infectious Diseases Johns Hopkins Bayview Medical Center. Conflict of Interest: Has no real or apparent conflicts of interest to report.	Norah Terrault, MD, MPH terrault@usc.edu Dr. Norah Terrault is a transplant hepatologist, the Neil Kaplowitz Professor of Medicine and Chief of Gastrointestinal and Liver Diseases Division at the Keck School of Medicine of University of Southern California in Los Angeles, California. Conflict of Interest: Dr. Terrault receives a salary from AASLD, royalties from Elsevier, and institutional grant support from NIH; GSK; Genentech-Roche; Helio Health; Durect Corp; Eiger Pharmaceuticals, and ImmunoCore.
Grace Wang, MD gwang@assemblybio.com Y. Grace Wang, MD is the VP of Clinical Development at Assembly Bioscience. Conflict of Interest: Has an ownership interest in Assembly Biosciences.